North American researchers eye ALS vaccine

Oct 05, 2007

Researchers from U.S. and Canadian universities said they are working on a vaccine for treating the degenerative condition known as Lou Gehrig's disease.

The researchers are developing a vaccine that would target a toxic protein in people with the genetic mutation -- found in a small percentage of cases of the neuro-muscular disease amyotrophic lateral sclerosis, the Montreal Gazette reported Friday.

"The particular protein that has been the subject of much discussion is one that is made in every cell of the body in very high quantities," Harvard University neuro-scientist Robert Brown said at the Montreal Neurological Institute, which is conducting a symposium this week on ALS.

In people with the genetic mutation, the protein becomes toxic, changing in a way that causes it to become unstable, "probably impairing many, many aspects of the motor neurons that will die," he said.

Brown and researchers from Universite Laval in Quebec City are conducting more research on the Canadians' work that showed such a vaccine targeting the toxic protein was effective in lab mice genetically bred with ALS.

Copyright 2007 by United Press International

Explore further: Prescription drug monitoring programs offer multiple benefits

Related Stories

The protein problem

Jun 17, 2015

The importance of proteins is difficult to overstate; they play a critical role in countless biological processes. An enhanced understanding of their structure and function is essential to advancing the state ...

Bacterial protein serves as sensor

Jun 10, 2015

A German-French team led by Prof. Dr. Jan C. Behrends and Dr. Gerhard Baaken from the University of Freiburg and Dr. Abdelghani Oukhaled from the Universities of Evry and Cergy-Pontoise has developed a method ...

Recommended for you

Teva to lift bid for Mylan: report

12 hours ago

Israeli pharmaceutical giant Teva plans to increase its bid for rival Mylan and could announce the move as soon as this week, according to a US media report Monday.

Vaccine for West Nile Virus enters human clinical trials

16 hours ago

A clinical trial of a new investigational vaccine designed to protect against West Nile Virus infection will be sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes ...

FDA clears drug for leading form of cystic fibrosis

Jul 02, 2015

Federal health officials have approved a new combination drug for the most common form of cystic fibrosis, the debilitating inherited disease that causes internal mucus buildup, lung infections and early death. But it will ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.